Santhera Pharmaceuticals Holding AG
SANN
Pozycja w akcjach
#16591
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company,... Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Cena akcji
$17.23
Kapitalizacja rynkowa
$263.68M
Zmiana (1 dzień)
-4.18%
Zmiana (1 rok)
38.54%
Kraj
CH
Handel Santhera Pharmaceuticals Holding AG (SANN)
Kategoria
Healthcare
Historia ceny akcji dla Santhera Pharmaceuticals Holding AG (SANN)
Najwyższa cena zamknięcia: $18.92 dnia 2026-10-01
Najniższa cena zamknięcia: $44.13 dnia 2014-03-01
Najniższa cena zamknięcia: $44.13 dnia 2014-03-01
Historia cen akcji firmy Santhera Pharmaceuticals Holding AG od 2014 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2026 (TTM) | 22.24% |
| 2025 | 42.98% |
| 2024 | -6.16% |
| 2023 | 41.12% |
| 2022 | -43.82% |
| 2021 | -53.14% |
| 2020 | -74.39% |
| 2019 | -17.31% |
| 2018 | -49.89% |
| 2017 | -38.99% |
| 2016 | -48.52% |
| 2015 | -16.32% |
| 2014 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $535.97 | 25.69% |
US
|
|
| $190.72 | 610.32% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $889.32 | 9.23% |
NL
|
